Lepu Biopharma Co., Ltd. and Beijing DP Tech Co., Ltd. (DP Technology) have recently announced a significant milestone in their Antibody-Drug Conjugate (ADC) drug collaboration. This partnership has effectively integrated DP's ADC Linker

Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration with Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies.

Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced they have entered into a global strategic collaboration to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor, being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.

Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical Devices

Remedy Pharmaceuticals, a leader in stroke drug development, announced today that a Type C meeting held with the U.S. Food and Drug Administration (FDA) on October 16, 2024, provided valuable feedback on the design of a Phase 3 trial of its investigational drug

SK Biopharmaceuticals, a biotech company, announced that it has entered into an agreement with the Korea Institute of Radiological and Medical Sciences (KIRAMS), Korea's premier research institution dedicated to the study and advancement

Lunit a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a strategic collaboration with AstraZeneca, a leading pharmaceutical company, to develop AI-powered digital pathology solutions.

NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, announces that it has dosed the first Charcot-Marie-Tooth (CMT) disease

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN)

Syndax Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia